Physician profile
Richard Strulson
NPI 1639118938
$5,734.69
in general payments reported to CMS, 2019-2025
39 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $894 · 2021: $1,514 · 2022: $1,008 · 2023: $556 · 2024: $368 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $967.67 | 2021-2025 | Ubrelvy, Vraylar |
| Pfizer INC. | $559.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $529.48 | 2019-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $529.44 | 2020-2025 | Airsupra, Breztri |
| Almatica Pharma LLC | $317.21 | 2021-2025 | Loreev Xr, Gralise |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.10 | 2019-2021 | |
| Allergan, INC. | $274.98 | 2019-2020 | |
| Novo Nordisk INC | $235.09 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $196.65 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $188.41 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $165.88 | 2021-2022 | |
| Lilly USA, LLC | $161.18 | 2023-2025 | Mounjaro, Trulicity |
| Amgen INC. | $161.09 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $156.04 | 2019-2022 | |
| Amarin Pharma, INC. | $155.15 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Strulson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.